Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$64.70 USD

64.70
7,412,684

+0.85 (1.33%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $64.62 -0.08 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Mark Vickery headshot

Top Stock Reports for FEMSA, NextEra Energy & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.

Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

Smart Beta ETF report for ONEY

Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?

Smart Beta ETF report for CLRG

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Andrew Rocco headshot

Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead

Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.

Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE